Memory Pharmaceuticals Corp., of Montvale, N.J., appointed Vaughn M. Kailian interim president and CEO; Jim Sulat, the previous president and CEO, will be chief financial executive on a part-time basis.

Mersana, of Cambridge, Mass., named Timothy B. Lowinger chief scientific officer.

Nektar Therapeutics, of San Carlos, Calif., appointed Hoyoung Huh to its board of directors.

Neurochem Inc., of Laval, Quebec, appointed Gary Schmid CEO of the new nutraceuticals business the company is creating.

Neurogen Corp., of Branford, Conn., appointed John LaMattina to its board.

Nile Therapeutics Inc., of Berkeley, Calif., appointed Gregory W. Schafer to its board of directors and named him chairman of the audit committee.

North Carolina Biotechnology Center, of Research Triangle Park, N.C., named Yonnie Butler business development director of its business & technology development unit.

NPS Pharmaceuticals Inc., of Bedminster, N.J. announced that its board of directors elected Peter Tombros chairman of the board and appointed Francois Nader as a director.

OPKO Health Inc., of Miami, appointed Thomas E. Beier and Richard C. Pfenniger Jr. to its board of directors.

Oxford Genome Sciences Ltd., of Oxford, UK, appointed Elke Jaeger to its scientific and clinical advisory board.

PCI Biotech, of Oslo, Norway, named Per Walday chief executive officer.

PeriCor Therapeutics, of New York, appointed K. Tucker Andersen to its board of directors.

Perlegen Sciences, of Mountain View, Calif., named Kevin Cooksy vice president of business development, appointed Julie Brooks general counsel and corporate secretary and named Brenda Rogers vice president of human resources.

PharmAthene Inc., of Annapolis, Md., named Joan Fusco senior vice president of operations.

PolyMedix Inc., of Randor, Pa., appointed Brian Anderson to its board of directors.

Poniard Pharmaceuticals, of South San Francisco, appointed Robert De Jager chief medical officer.

Profectus BioSciences Inc., of Baltimore, named Shawn Patrick O'Brien CEO.